OBJECTIVE: Diet-induced obesity (DIO) in mice causes vascular inflammation and insulin resistance that are accompanied by decreased endothelial-derived NO production. We sought to determine whether reduced NO-cGMP signaling contributes to the deleterious effects of DIO on the vasculature and, if so, whether these effects can be blocked by increased vascular NO-cGMP signaling. METHODS AND RESULTS: By using an established endothelial cell culture model of insulin resistance, exposure to palmitate, 100 micromol/L, for 3 hours induced both cellular inflammation (activation of IKK beta-nuclear factor-kappaB) and impaired insulin signaling via the insulin receptor substrate-phosphatidylinositol 3-kinase pathway. Sensitivity to palmitate-induced endothelial inflammation and insulin resistance was increased when NO signaling was reduced using an endothelial NO synthase inhibitor, whereas endothelial responses to palmitate were blocked by pretreatment with either an NO donor or a cGMP analogue. To investigate whether endogenous NO-cGMP signaling protects against vascular responses to nutrient excess in vivo, adult male mice lacking endothelial NO synthase were studied. As predicted, both vascular inflammation (phosphorylated I kappaB alpha and intercellular adhesion molecule levels) and insulin resistance (phosphorylated Akt [pAkt] and phosphorylated eNOS [peNOS] levels) were increased in endothelial NO synthase(-/-) (eNOS(-/-)) mice, reminiscent of the effect of DIO in wild-type controls. Next, we asked whether the vascular response to DIO in wild-type mice can be reversed by a pharmacological increase of cGMP signaling. C57BL6 mice were either fed a high-fat diet or remained on a low-fat diet for 8 weeks. During the final 2 weeks of the study, mice on each diet received either placebo or the phosphodiesterase-5 inhibitor sildenafil, 10 mg/kg per day orally. In high-fat diet-fed mice, vascular inflammation and insulin resistance were completely prevented by sildenafil administration at a dose that had no effect in mice fed the low-fat diet. CONCLUSIONS: Reduced signaling via the NO-cGMP pathway is a mediator of vascular inflammation and insulin resistance during overnutrition induced by high-fat feeding. Therefore, phosphodiesterase-5, soluble guanylyl cyclase, and other molecules in the NO-cGMP pathway (eg, protein kinase G) constitute potential targets for the treatment of vascular dysfunction in the setting of obesity.
OBJECTIVE: Diet-induced obesity (DIO) in mice causes vascular inflammation and insulin resistance that are accompanied by decreased endothelial-derived NO production. We sought to determine whether reduced NO-cGMP signaling contributes to the deleterious effects of DIO on the vasculature and, if so, whether these effects can be blocked by increased vascular NO-cGMP signaling. METHODS AND RESULTS: By using an established endothelial cell culture model of insulin resistance, exposure to palmitate, 100 micromol/L, for 3 hours induced both cellular inflammation (activation of IKK beta-nuclear factor-kappaB) and impaired insulin signaling via the insulin receptor substrate-phosphatidylinositol 3-kinase pathway. Sensitivity to palmitate-induced endothelial inflammation and insulin resistance was increased when NO signaling was reduced using an endothelial NO synthase inhibitor, whereas endothelial responses to palmitate were blocked by pretreatment with either an NO donor or a cGMP analogue. To investigate whether endogenous NO-cGMP signaling protects against vascular responses to nutrient excess in vivo, adult male mice lacking endothelial NO synthase were studied. As predicted, both vascular inflammation (phosphorylated I kappaB alpha and intercellular adhesion molecule levels) and insulin resistance (phosphorylated Akt [pAkt] and phosphorylated eNOS [peNOS] levels) were increased in endothelial NO synthase(-/-) (eNOS(-/-)) mice, reminiscent of the effect of DIO in wild-type controls. Next, we asked whether the vascular response to DIO in wild-type mice can be reversed by a pharmacological increase of cGMP signaling. C57BL6 mice were either fed a high-fat diet or remained on a low-fat diet for 8 weeks. During the final 2 weeks of the study, mice on each diet received either placebo or the phosphodiesterase-5 inhibitor sildenafil, 10 mg/kg per day orally. In high-fat diet-fed mice, vascular inflammation and insulin resistance were completely prevented by sildenafil administration at a dose that had no effect in mice fed the low-fat diet. CONCLUSIONS: Reduced signaling via the NO-cGMP pathway is a mediator of vascular inflammation and insulin resistance during overnutrition induced by high-fat feeding. Therefore, phosphodiesterase-5, soluble guanylyl cyclase, and other molecules in the NO-cGMP pathway (eg, protein kinase G) constitute potential targets for the treatment of vascular dysfunction in the setting of obesity.
Authors: Julio E Ayala; Deanna P Bracy; Brianna M Julien; Jeffrey N Rottman; Patrick T Fueger; David H Wasserman Journal: Diabetes Date: 2007-01-17 Impact factor: 9.461
Authors: Mark R Duranski; John W Elrod; John W Calvert; Nathan S Bryan; Martin Feelisch; David J Lefer Journal: Am J Physiol Heart Circ Physiol Date: 2006-07-28 Impact factor: 4.733
Authors: Francis Kim; Kelly A Tysseling; Julie Rice; Matilda Pham; Lutfiyah Haji; Byron M Gallis; Arnold S Baas; Pathmaja Paramsothy; Cecilia M Giachelli; Marshall A Corson; Elaine W Raines Journal: Arterioscler Thromb Vasc Biol Date: 2005-02-24 Impact factor: 8.311
Authors: Francis Kim; Matilda Pham; Ian Luttrell; Douglas D Bannerman; Joan Tupper; Joshua Thaler; Thomas R Hawn; Elaine W Raines; Michael W Schwartz Journal: Circ Res Date: 2007-05-03 Impact factor: 17.367
Authors: Annamalai Senthilkumar; Ray D Smith; Jayant Khitha; Neeraj Arora; Srikar Veerareddy; Will Langston; John H Chidlow; Shayne C Barlow; Xinjun Teng; Rakesh P Patel; David J Lefer; Christopher G Kevil Journal: Arterioscler Thromb Vasc Biol Date: 2007-06-21 Impact factor: 8.311
Authors: Paolo Serafini; Kristen Meckel; Michael Kelso; Kimberly Noonan; Joseph Califano; Wayne Koch; Luigi Dolcetti; Vincenzo Bronte; Ivan Borrello Journal: J Exp Med Date: 2006-11-13 Impact factor: 14.307
Authors: Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris Journal: Free Radic Biol Med Date: 2016-12-16 Impact factor: 7.376
Authors: Andrew M Cheng; Norma Rizzo-DeLeon; Carole L Wilson; Woo Je Lee; Sanshiro Tateya; Alexander W Clowes; Michael W Schwartz; Francis Kim Journal: Am J Physiol Endocrinol Metab Date: 2014-08-12 Impact factor: 4.310
Authors: Dennis M J Muris; Alfons J H M Houben; Miranda T Schram; Coen D A Stehouwer Journal: Rev Endocr Metab Disord Date: 2013-03 Impact factor: 6.514
Authors: Brian P Dick; Ryan McMahan; Taft Knowles; Lev Becker; Sina A Gharib; Tomas Vaisar; Tomasz Wietecha; Kevin D O'Brien; Karin E Bornfeldt; Alan Chait; Francis Kim Journal: Arterioscler Thromb Vasc Biol Date: 2020-01-30 Impact factor: 8.311
Authors: Hyun-Ju Jang; Hae-Suk Kim; Daniel H Hwang; Michael J Quon; Jeong-a Kim Journal: Am J Physiol Endocrinol Metab Date: 2013-03-26 Impact factor: 4.310